読み込み中
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
前日終値
$5.07
+$0.17 · +3.47%
日中の時刻はETです。市場データは遅延する場合があります。
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
日中レンジ
現在 $5.07
52週レンジ
現在 $5.07
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
42
まちまち
リスク
54
やや高いリスク
モメンタム
81
強い上昇
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
日中レンジ
現在 $5.07
52週レンジ
現在 $5.07
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | — | — | 172.1万 USD | 111.8万 USD |
| 粗利益 | — | — | — | −172.1万 USD | −111.8万 USD |
| 研究開発 | 2380.7万 USD | 2281.1万 USD | 1614.8万 USD | 2799万 USD | 3042.3万 USD |
| 販売・一般管理 | 916万 USD | 521.8万 USD | 671.9万 USD | 1089.8万 USD | 1245.2万 USD |
| 営業費用 | 3296.7万 USD | 2802.9万 USD | 2286.7万 USD | 3716.7万 USD | 4202.7万 USD |
| 受取利息 | — | 44.2万 USD | 54.8万 USD | 26.7万 USD | 46.8万 USD |
| 支払利息 | 68.5万 USD | 152.5万 USD | 171.1万 USD | 133.9万 USD | — |
| 減価償却費と償却費 | 145.8万 USD | 162.2万 USD | 182.2万 USD | 172.1万 USD | 111.8万 USD |
| 営業利益 | −3296.7万 USD | −2802.9万 USD | −2286.7万 USD | −3888.8万 USD | −4314.5万 USD |
| 純利益 | −3416.9万 USD | −2902.2万 USD | −2386.5万 USD | −3952.5万 USD | −4071.3万 USD |
会社概要が更新されました 2026年10月11日.
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
